RMRosa del Carmen Milán-Segovia

Rosa del Carmen Milán-Segovia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rosa del Carmen Milán-Segovia has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine Learning-Assisted Screening in Systematic Reviews: A Case Study on Pelvic Inflammatory Disease Prevention

    by Martín Daniel Guadarrama-Atrizco, Francisco Javier Prado-Galbarro, Carlos Sánchez-Piedra, Rosa del Carmen Milán-Segovia, Karina Sánchez-Herrera, Juan Manuel Martínez-Núñez

    This study evaluates ASReview, an open-source machine learning application for study selection in systematic literature reviews, using data from a review of whether screening for sexually transmitted infections reduces the incidence of pelvic inflammatory disease. A systematic literature review was conducted in accordance with the PRISMA guidelines, and manual screening produced a fully labeled dataset that served as the reference standard. ASReview was configured with four machine learning classifiers (Naïve Bayes, Random Forest, Support Vector Machines, and Logistic Regression) and two feature extraction methods (TF-IDF and Doc2Vec). Simulation experiments assessed screening efficiency under sampling-based and heuristic stopping rules. The systematic review suggested that annual screening for sexually transmitted infections may reduce the incidence of pelvic inflammatory disease by up to 40% compared with routine practice, although the evidence base was limited. In the simulation experiments, Naïve Bayes with TF-IDF achieved the highest recall and screening efficiency, particularly in datasets with a low prevalence of relevant records. Conservative stopping rules increased the likelihood of complete retrieval but required greater screening effort. Overall, these findings highlight the limited and heterogeneous evidence on sexually transmitted infection screening for pelvic inflammatory disease prevention and show that ASReview may improve the efficiency of study selection when evaluated within a real systematic review workflow.

  • Vancomycin Overdose and Infusion Rate Error Leading to a Mixed Anticholinergic-Type Syndrome in a Hemodialysis Patient: A Case Report

    by Waldo-Rodríguez Itzayana Guadalupe, Arriaga-García Francisco Javier, Romano-Moreno Silvia, Medellín-Garibay Susanna Edith, Martínez-Núñez Juan Manuel, Castro-Pastrana Lucila Isabel, Milán-Segovia Rosa del Carmen

    Objective: To describe a mixed anticholinergic-type syndrome not previously associated with vancomycin in a patient with end-stage renal disease on hemodialysis, highlighting the impact of dosing and infusion rate errors. Case: A 61-year-old man with stage 5 chronic kidney disease on hemodialysis was admitted to the internal medicine unit for a catheter-related infection. Vancomycin was initiated at 1 g every 12 hours, infused at 16.6 mg/min. After four doses, the patient developed transient amaurosis, tachycardia, hyperthermia, xerostomia, xeroderma, confusion, agitation, and panic, consistent with a mixed anticholinergic-type syndrome. Symptoms resolved after discontinuation of vancomycin and subsequent hemodialysis. Discussion/Conclusions: This case demonstrates a definite association between vancomycin overdose with rapid infusion and the development of a mixed anticholinergic-type syndrome in a patient on hemodialysis. These findings underscore the importance of careful dose adjustment and strict control of infusion rates in advanced renal disease.

  • Acute Pancreatitis Associated with Propofol in a Patient with End-Stage Renal Disease: Diagnostic Challenges and Confounding Factors

    by Itzayana Guadalupe Waldo-Rodríguez, Francisco Javier Arriaga-García, Silvia Romano-Moreno, Susanna Edith Medellín-Garibay, Juan Manuel Martínez-Núñez, Lucila Isabel Castro-Pastrana, Rosa del Carmen Milán-Segovia

    Objective: Acute pancreatitis is an inflammatory disorder of the pancreas with diverse etiologies, including rare drug-induced causes such as propofol. Propofol-associated acute pancreatitis has been linked to hypertriglyceridemia; however, causal attribution is particularly challenging in patients with chronic kidney disease, due to metabolic disturbances and overlapping clinical features. Case: We report the case of a 49-year-old female with end-stage chronic kidney disease admitted with septic shock requiring mechanical ventilation and continuous sedation with propofol infused at 70 mg/h. After 8 days of therapy, she developed progressive hypertriglyceridemia followed by clinical and biochemical findings consistent with acute pancreatitis. Common etiologies were excluded, and the temporal relationship supported a probable adverse drug reaction. Discussion/Conclusions: This case highlights the diagnostic and causal complexity of acute pancreatitis in critically ill patients with advanced chronic kidney disease and underscores the importance of vigilant metabolic monitoring and multidisciplinary medication review during propofol therapy.

  • Open Access

    Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections

    by Frida S. Boer-Pérez, Victoria Lima-Rogel, Silvia Romano-Moreno, Ana R. Mejía-Elizondo, Susanna E. Medellín-Garibay, Paula Schaiquevich, Daniel E. Noyola-Cherpitel, Ana S. Rodríguez-Báez, Cristian J. Rodríguez-Pinal, Rosa del C. Milán-Segovia

    Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (>75%) were at risk of overexposure (trough piperacillin plasma concentration >50 mg/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1−4 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.


  • Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients

    by Omar Rodríguez-Pérez, Juan Manuel López-Quijano, Cristian Jazmín Rodríguez-Pinal, Juan Manuel Vargas-Morales, Silvia Romano-Moreno, Rosa del Carmen Milán-Segovia, Antonio Augusto Gordillo-Moscoso, Úrsula Fabiola Medina-Moreno, Susanna Edith Medellín-Garibay

    Warfarin dosing guided by INR fails to account for pharmacokinetic/pharmacodynamic variability, leading to suboptimal outcomes; genetic and clinical factors, such as VKORC1 polymorphism and comorbidities, could refine dosing strategies and improve anticoagulation safety. The aim of this was to identify the main determinants of INR variability in Mexican patients under long-term anticoagulation therapy. For this purpose, patients undergoing warfarin treatment were included and a clinical data was retrieved from medical record. A bioanalytical HPLC method to quantify warfarin (CPW) and its primary metabolite, 7-OH warfarin (CP7OH), in plasma samples was standardized and validated. INR variability was assessed in relation to Charlson comorbidity index (CCI), warfarin dose, drug interactions, vitamin K intake, CPW, CP7OH, metabolic ratio, and VKORC1 1693 polymorphism using univariate and multivariate analysis. The results showed that among 22 patients (64% women) with atrial fibrillation and aortic-mitral valve replacement, warfarin dosing ranged from 8.75 to 55 mg/week (median: 22.5 mg/week). Over half (68.2%) did not achieve the therapeutic INR goal (2.0–3.5). VKORC1 1693 genotype frequencies were GG (36%), GA (50%), and AA (14%), with AA carriers requiring lower maintenance doses (p<0.01). Multivariate analysis incorporating CCI, CPW and CP7OH explained up to 70% of INR variability (p<0.01). Furthermore, currently reported dosing algorithms showed limited accuracy in predicting the appropriate warfarin dose in this cohort. Overall, INR variability depends on plasma warfarin levels, metabolite concentration, and key comorbidities. Therefore, tailored population models are essential to optimize anticoagulation therapy in Mexico. This research highlights the need for more inclusive studies incorporating genetic and clinical factors to refine warfarin dosing and improve outcomes. Graphical abstract Created in BioRender. Rodriguez, O. (2025) https://BioRender.com/t2ww5to.


  • Open Access

    Preclinical Evaluation of the Anticoagulant Effect of an Aqueous Extract of Snow Mountain Garlic

    by Isabel Clark-Montoya, Rosa del Carmen Milán-Segovia, Obed Lemus-Rojero, Osmar Antonio Jaramillo-Morales, Bertha Júarez-Flores, Yolanda Terán-Figueroa

    Background/Objectives: In the genus Allium, it has been shown that some organosulfate compounds of common garlic and onion have an antiplatelet effect. Still, little is known about the anticoagulant activity of the species, Allium ampeloprasum L., specifically Snow mountain garlic; due to its growth site at 6000 m above sea level at temperatures of −10 °C, it could contain different organosulfate compounds. Methods: This study evaluated the anticoagulant effect of a lyophilized aqueous extract of S. mountain garlic in vivo, toxicity in male Wistar rats for 90 days, and the organosulfate compounds present. Results: There was a significant increase (p < 0.05) in the area under the curve for bleeding time at doses of 500 and 1000 mg/kg/d of lyophilized aqueous extract of Snow mountain garlic and 100 mg/kg/d of acetylsalicylic acid. The ED50 was 366 ± 2.43 mg/kg. For chronic toxicity in vivo, no histopathological alterations were found at doses below 500 mg/kg. On the other hand, organosulfate compounds were found in the lyophilized aqueous extract of S. mountain garlic that had not been documented to have an anticoagulant effect. Conclusions: We conclude that S. mountain garlic contains anticoagulant compounds which may be candidates for the treatment of thrombosis.


  • Open Access

    Anticoagulant Effect of Snow mountain garlic: In Vitro Evaluation of Aqueous Extract

    by Isabel Clark-Montoya, Yolanda Terán-Figueroa, Denisse de Loera, Darío Gaytán-Hernández, Jorge Alejandro Alegría-Torres, Rosa del Carmen Milán-Segovia

    Snow mountain garlic is traditionally eaten by Himalayan locals for its medicinal properties. Although different species of the genus Allium are known to have other biological effects, such as antiplatelet and antithrombotic activities, little is known about the anticoagulant effect of Snow mountain garlic, a member of the genus Allium. Therefore, the present study examined the in vitro anticoagulant effect of the aqueous extract, the lyophilized aqueous extract, and the isoflavone extract from the lyophilized aqueous extract of Snow mountain garlic in samples from 50 human blood donors. Compared to the control, concentrations of 25, 12.5, and 6.25 mg/100 µL lengthened the clotting times of prothrombin, and concentrations of 25 and 12.5 mg/100 µL lengthened the activated partial thromboplastin time (p ˂ 0.05). The isoflavone extract from the lyophilized aqueous extract containing isoflavones, organosulfur compounds, a polyphenol, and a steroid glycoside showed a significant effect (p ˂ 0.05) on the prothrombin time and the activated partial thromboplastin time at a dose of 20 µL (volume) compared to the control. The results regarding the use of Snow mountain garlic as a preventive measure and aid in treating thromboembolic disease are promising.


  • UPLC–MS/MS method for fluconazole determination in plasma and its application in Mexican patients with candidaemia

    by Karla Paulina Valero Rivera, Martin Magaña Aquino, Julia Sagahón Azúa, María del Carmen Romero Méndez, Susanna Edith Medellín Garibay, Rosa del Carmen Milán Segovia, Fidel Martínez Gutiérrez, Silvia Romano Moreno

    Aim: An accurate and fast ultra-high performance liquid chromatography coupled with tandem mass spectrometry analytical method was developed and validated for quantifying fluconazole levels in human plasma according to the US FDA guidelines. Materials & methods: A simple protein precipitation by acetonitrile was employed for the sample preparation. The chromatographic separation was carried out using isocratic elution of water (0.1% formic acid) and acetonitrile on an Acquity ultra-high performance liquid chromatography HSS T3 column. Samples from ten adult patients diagnosed with candidemia who received fluconazole treatment were analyzed. Results & conclusion: The method demonstrated excellent linearity and stability within the 1-50 mu g/ml range (r(2) >0.999). The intraday and interday precision were determined with coefficient of variation values ranging from 1.4 to 4.38% and 2.8 to 6.6%, respectively. This rapid and selective method has successfully analyzed 27 plasma samples. The straightforward sample preparation in a single step and the reduced analysis time make this method suitable for adult patients with candidemia, leading to improved clinical outcomes.


  • External Evaluation of Population Pharmacokinetic Models of Piperacillin in Preterm and Term Patients from Neonatal Intensive Care

    by Frida S. Boer-Pérez, Victoria Lima-Rogel, Ana R. Mejía-Elizondo, Susanna E. Medellín-Garibay, Ana S. Rodríguez-Báez, Cristian J. Rodríguez-Pinal, Rosa del C. Milán-Segovia, Silvia Romano-Moreno

    Background and Objectives Piperacillin/tazobactam is extensively used off-label to treat late-onset neonatal sepsis, but safety and pharmacokinetic data in this population are limited. Additionally, the organic immaturity of the newborns contributes to a high piperacillin pharmacokinetic variability. This affects the clinical efficacy of the antibiotic treatment and increases the probability of developing drug resistance. This study aimed to evaluate the predictive performance of reported piperacillin population pharmacokinetic models for their application in a model-informed precision dosing strategy in preterm and term Mexican neonatal intensive care patients. Methods Published population pharmacokinetic models for piperacillin which included neonates in their study population were identified. From the reference models, structured models, population pharmacokinetic parameters, and interindividual and residual variability data were extracted to be replicated in pharmacokinetic software (NONMEM® version 7.4). For the clinical study, a sampling schedule was designed, and 2–3 blood samples of 250 µL were taken from neonates who met the inclusion criteria. Piperacillin plasma concentrations were determined by liquid chromatography/tandem mass spectrometry. The clinical treatment data were collected, and piperacillin plasma concentrations were estimated using reference pharmacokinetic models for an a priori or Bayesian approach. Statistical methods were used in terms of bias and precision to evaluate the differences between observed and estimated neonatal piperacillin plasma concentrations with the different approaches and to identify the pharmacokinetic model that best fits the neonatal data. Results A total of 70 plasma samples were collected from 25 neonatal patients, of which 15 were preterm neonates. The overall median value (range) postnatal age, gestational age, body weight, and serum creatinine at the sampling collecting day were 12 (3–26) days, 34.2 (26–41.1) weeks, 1.78 (0.08–3.90) Kg, 0.47 (0.20–0.90) mg/dL, respectively. Three population pharmacokinetic models for piperacillin in infants up to 2 months were identified, and their predictive performance in neonatal data was evaluated. No pharmacokinetic model was suitable for our population using an a priori approach. The model published by Cohen-Wolkowiez et al. in 2014 with a Bayesian approach showed the best performance of the pharmacokinetic models evaluated in our neonatal data. The procedure requires two blood samples (predose and postdose), and, when applied, it predicted 66.6% of the observations with a relative median absolute predicted error of less than 30%. Conclusions The population pharmacokinetic model developed by Cohen-Wolkowiez et al. in 2014 demonstrated superior performance in predicting the plasma concentration of piperacillin in preterm and term Mexican neonatal intensive care patients. The Bayesian approach, including two different piperacillin plasma concentrations, was clinically acceptable regarding bias and precision. Its application for model-informed precision dosing can be an option to optimize the piperacillin dosage in our population.


  • Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders

    by Cinthya Eloisa Chávez Castillo, Susanna Edith Medellín Garibay, Rosa del Carmen Milán Segovia, Sergio Zarazúa Guzmán, Helgi Jung Cook, Marisol Orocio Contreras, Silvia Romano Moreno

    This study aimed to characterize the population pharmacokinetics of sertraline in Mexican patients with psychiatric and substance use disorders. Fifty‐nine patients (13 to 76 years old) treated with doses of sertraline between 12.5 and 100 mg/day were included. Plasma sertraline concentrations were determined in blood samples and five of the main substances of abuse were determined by rapid tests in urine samples. Demographic, clinical, and pharmacogenetic factors were also evaluated. Population pharmacokinetic analysis was performed using NONMEM software with first‐order conditional estimation method. A one‐compartment model with proportional residual error adequately described the sertraline concentrations versus time. CYP2D6*2 polymorphism and CYP2C19 phenotypes significantly influenced sertraline clearance, which had a population mean value of 66 L/h in the final model. The absorption constant and volume of distribution were fixed at 0.855 1/h and 20.2 L/kg, respectively. The model explained 11.3% of the interindividual variability in sertraline clearance. The presence of the CYP2D6*2 polymorphism caused a 23.1% decrease in sertraline clearance, whereas patients with intermediate and poor phenotype of CYP2C19 showed 19.06% and 48.26% decreases in sertraline clearance, respectively. The model was internally validated by bootstrap and visual predictive check. Finally, stochastic simulations were performed to propose dosing regimens to achieve therapeutic levels that contribute to improving treatment response.